Pfizer has reached an agreement with the Trump administration to offer medicines at prices comparable to those found in other developed countries, marking the first drug maker to sign on under the administration's most favored nation (MFN) drug pricing initiative. As part of the deal, Pfizer will launch a direct-to-consumer website, TrumpRx, allowing Americans to purchase discounted medications at an average of 50% off list price. The plan aims to improve affordability and access without affecting commercially insured patients. This move follows broader industry discussions on drug pricing reform and potential tariffs on pharmaceutical imports.